Thomas Edward Hamilton, Director at Larimar Therapeutics, Inc. (LRMR), bought 50,000 shares at $3.34 ($167K) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Open-market purchase of $167k LRMR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| LRMR | BUY | 2022-09-20 | $1000K | — | Filing → |
| LRMR | BUY | 2021-07-02 | $992K | — | Filing → |
| NLY | SELL | 2021-05-04 | $734K | — | Filing → |